Company
4TEEN4 Pharmaceuticals GmbH
Targeting a key pathological driver of mortality in shock
Also known as 4TEEN4 Pharmaceuticals
- Status
- Operatingas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Headquarters
- Hennigsdorf, Germany
- Legal name
- 4TEEN4 Pharmaceuticals GmbH
- 4teen4.de (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
With our antibody invobenitug (procizumab) we aim to reverse life-threatening shock and restore organ function.
Funding snapshot
- Latest round
- Grant2026-07-02
Funding rounds
- Grant
- 2026-07-02
- Series C
- 2026-03-10
- Series C
- 2025-11-13
Products
- Other
- invobenitug (procizumab)
Loading relationship preview